Subsequently, it was reported that combined inhibition of the Notch and HER2 signaling pathways with GSI plus trastuzumab in orthotopic HER2+ BC xenografts could prevent or significantly reduce tumor growth by reversing trastuzumab resistance in resistant HER2+ cell models [91]. The gene discussed is ERBB2; the disease is breast cancer.